{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T03:15:21Z","timestamp":1789442121652,"version":"build-2803163510"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,12,5]],"date-time":"2019-12-05T00:00:00Z","timestamp":1575504000000},"content-version":"vor","delay-in-days":4,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81472834"],"award-info":[{"award-number":["81472834"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The dysfunction of type I interferon (IFN) signaling is an important mechanism of immune escape and metastasis in tumors. Increased NOS1 expression has been detected in melanoma, which correlated with dysfunctional IFN signaling and poor response to immunotherapy, but the specific mechanism has not been determined. In this study, we investigated the regulation of NOS1 on the interferon response and clarified the relevant molecular mechanisms.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>After stable transfection of A375 cells with NOS1 expression plasmids, the transcription and expression of IFN\u03b1-stimulated genes (ISGs) were assessed using pISRE luciferase reporter gene analysis, RT-PCR, and western blotting, respectively. The effect of NOS1 on lung metastasis was assessed in melanoma mouse models. A biotin-switch assay was performed to detect the S-nitrosylation of HDAC2 by NOS1. ChIP-qPCR was conducted to measure the binding of HDAC2, H4K16ac, H4K5ac, H3ac, and RNA polymerase II in the promoters of ISGs after IFN\u03b1 stimulation. This effect was further evaluated by altering the expression level of HDAC2 or by transfecting the HDAC2-C262A\/C274A site mutant plasmids into cells. The coimmunoprecipitation assay was performed to detect the interaction of HDAC2 with STAT1 and STAT2. Loss-of-function and gain-of-function approaches were used to examine the effect of HDAC2-C262A\/C274A on lung metastasis. Tumor infiltrating lymphocytes were analyzed by flow cytometry.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>HDAC2 is recruited to the promoter of ISGs and deacetylates H4K16 for the optimal expression of ISGs in response to IFN\u03b1 treatment. Overexpression of NOS1 in melanoma cells decreases IFN\u03b1-responsiveness and induces the S-nitrosylation of HDAC2-C262\/C274. This modification decreases the binding of HDAC2 with STAT1, thereby reducing the recruitment of HDAC2 to the ISG promoter and the deacetylation of H4K16. Moreover, expression of a mutant form of HDAC2, which cannot be nitrosylated, reverses the inhibition of ISG expression by NOS1 in vitro and decreases NOS1-induced lung metastasis and inhibition of tumor infiltrating lymphocytes in a melanoma mouse model.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This study provides evidence that NOS1 induces dysfunctional IFN signaling to promote lung metastasis in melanoma, highlighting NOS1-induced S-nitrosylation of HDAC2 in the regulation of IFN signaling via histone modification.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s13046-019-1448-9","type":"journal-article","created":{"date-parts":[[2019,12,5]],"date-time":"2019-12-05T19:02:54Z","timestamp":1575572574000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["NOS1 inhibits the interferon response of cancer cells by S-nitrosylation of HDAC2"],"prefix":"10.1186","volume":"38","author":[{"given":"Pengfei","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangyan","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keyi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengqiu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianli","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sisi","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenwen","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianbing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuo","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhili","family":"Rong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingtao","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anghui","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manzhao","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuzhen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,5]]},"reference":[{"issue":"7","key":"1448_CR1","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/nri3845","volume":"15","author":"Z Laurence","year":"2015","unstructured":"Laurence Z, Lorenzo G, Oliver K, Smyth MJ, Guido K. Type I interferons in anticancer immunity. Nat Rev Immunol. 2015;15(7):405\u201314.","journal-title":"Nat Rev Immunol"},{"issue":"11","key":"1448_CR2","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.it.2015.09.007","volume":"36","author":"AJ Minn","year":"2015","unstructured":"Minn AJ. Interferons and the immunogenic effects of Cancer therapy. Trends Immunol. 2015;36(11):725\u201337.","journal-title":"Trends Immunol"},{"issue":"22","key":"1448_CR3","doi-asserted-by":"publisher","first-page":"9010","DOI":"10.1073\/pnas.0901329106","volume":"106","author":"RJ Critchley-Thorne","year":"2009","unstructured":"Critchley-Thorne RJ, Simons DL, Yan N, Miyahira AK, Dirbas FM, Johnson DL, et al. Impaired interferon signaling is a common immune defect in human cancer. Proc Natl Acad Sci U S A. 2009;106(22):9010\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1448_CR4","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1038\/nri1961","volume":"6","author":"GP Dunn","year":"2006","unstructured":"Dunn GP, Koebel CM, Schreiber RD. Interferons, immunity and cancer immunoediting. Nat Rev Immunol. 2006;6:836.","journal-title":"Nat Rev Immunol"},{"issue":"11","key":"1448_CR5","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1038\/nm.3708","volume":"20","author":"S Antonella","year":"2014","unstructured":"Antonella S, Takahiro Y, Erika V, Kariman C, Enot DP, Julien A, et al. Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat Med. 2014;20(11):1301\u20139.","journal-title":"Nat Med"},{"key":"1448_CR6","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41698-019-0093-2","volume":"3","author":"NK Brockwell","year":"2019","unstructured":"Brockwell NK, Rautela J, Owen KL, Gearing LJ, Deb S, Harvey K, et al. Tumor inherent interferon regulators as biomarkers of long-term chemotherapeutic response in TNBC. NPJ Precision Oncol. 2019;3:21.","journal-title":"NPJ Precision Oncol"},{"issue":"2","key":"1448_CR7","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.ccell.2017.01.004","volume":"31","author":"KV Katlinski","year":"2017","unstructured":"Katlinski KV, Gui J, Katlinskaya YV, Ortiz A, Chakraborty R, Bhattacharya S, et al. Inactivation of interferon receptor promotes the establishment of immune privileged tumor microenvironment. Cancer Cell. 2017;31(2):194\u2013207.","journal-title":"Cancer Cell"},{"issue":"4","key":"1448_CR8","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1089\/10799900252952244","volume":"22","author":"S Picaud","year":"2002","unstructured":"Picaud S, Bardot B, De Maeyer E, Seif I. Enhanced tumor development in mice lacking a functional type I interferon receptor. J Interferon Cytokine Res. 2002;22(4):457\u201362.","journal-title":"J Interferon Cytokine Res"},{"issue":"8","key":"1448_CR9","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1038\/nm.2830","volume":"18","author":"BN Bidwell","year":"2012","unstructured":"Bidwell BN, Slaney CY, Withana NP, Sam F, Yuan C, Sherene L, et al. Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nat Med. 2012;18(8):1224\u201331.","journal-title":"Nat Med"},{"issue":"9","key":"1448_CR10","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1056\/NEJMoa1604958","volume":"375","author":"JM Zaretsky","year":"2016","unstructured":"Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med. 2016;375(9):819\u201329.","journal-title":"N Engl J Med"},{"issue":"2","key":"1448_CR11","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.cell.2016.08.069","volume":"167","author":"J Gao","year":"2016","unstructured":"Gao J, Shi LZ, Zhao H, Chen J, Xiong L, He Q, et al. Loss of IFN-gamma Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy. Cell. 2016;167(2):397\u2013404.e9.","journal-title":"Cell"},{"issue":"3","key":"1448_CR12","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1097\/00008390-200306000-00001","volume":"13","author":"DP Jackson","year":"2003","unstructured":"Jackson DP, Watling D, Rogers NC, Banks RE, Kerr IM, Selby PJ, et al. The JAK\/STAT pathway is not sufficient to sustain the antiproliferative response in an interferon-resistant human melanoma cell line. Melanoma Res. 2003;13(3):219\u201329.","journal-title":"Melanoma Res"},{"issue":"2","key":"1448_CR13","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.cytogfr.2014.11.008","volume":"26","author":"R Di Trolio","year":"2015","unstructured":"Di Trolio R, Simeone E, Di Lorenzo G, Buonerba C, Ascierto PA. The use of interferon in melanoma patients: a systematic review. Cytokine Growth Factor Rev. 2015;26(2):203\u201312.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"296","key":"1448_CR14","doi-asserted-by":"crossref","first-page":"re11","DOI":"10.1126\/stke.2962005re11","volume":"2005","author":"I Nusinzon","year":"2005","unstructured":"Nusinzon I, Horvath CM. Histone deacetylases as transcriptional activators? Role reversal in inducible gene regulation. Sci STKE. 2005;2005(296):re11.","journal-title":"Sci STKE"},{"issue":"26","key":"1448_CR15","doi-asserted-by":"publisher","first-page":"9578","DOI":"10.1073\/pnas.0400567101","volume":"101","author":"H-M Chang","year":"2004","unstructured":"Chang H-M, Paulson M, Holko M, Rice CM, Williams BRG, Mari\u00e9 I, et al. Induction of interferon-stimulated gene expression and antiviral responses require protein deacetylase activity. Proc Natl Acad Sci U S A. 2004;101(26):9578\u201383.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"25","key":"1448_CR16","doi-asserted-by":"publisher","first-page":"14742","DOI":"10.1073\/pnas.2433987100","volume":"100","author":"I Nusinzon","year":"2003","unstructured":"Nusinzon I, Horvath CM. Interferon-stimulated transcription and innate antiviral immunity require deacetylase activity and histone deacetylase 1. Proc Natl Acad Sci. 2003;100(25):14742\u20137.","journal-title":"Proc Natl Acad Sci"},{"issue":"39","key":"1448_CR17","doi-asserted-by":"publisher","first-page":"40362","DOI":"10.1074\/jbc.M406400200","volume":"279","author":"S Sakamoto","year":"2004","unstructured":"Sakamoto S, Potla R, Larner AC. Histone deacetylase activity is required to recruit RNA polymerase II to the promoters of selected interferon-stimulated early response genes. J Biol Chem. 2004;279(39):40362\u20137.","journal-title":"J Biol Chem"},{"issue":"29","key":"1448_CR18","doi-asserted-by":"publisher","first-page":"30358","DOI":"10.1074\/jbc.M401359200","volume":"279","author":"L Klampfer","year":"2004","unstructured":"Klampfer L, Huang J, Swaby LA, Augenlicht L. Requirement of histone deacetylase activity for signaling by STAT1. J Biol Chem. 2004;279(29):30358\u201368.","journal-title":"J Biol Chem"},{"issue":"1","key":"1448_CR19","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1096\/fj.11-191122","volume":"26","author":"L Icardi","year":"2012","unstructured":"Icardi L, Lievens S, Mori R, Piessevaux J, Cauwer LD, Bosscher KD, et al. Opposed regulation of type I IFN-induced STAT3 and ISGF3 transcriptional activities by histone deacetylases (HDACS) 1 and 2. FASEB J. 2012;26(1):240\u20139.","journal-title":"FASEB J"},{"issue":"12","key":"1448_CR20","doi-asserted-by":"publisher","first-page":"3194","DOI":"10.1084\/jem.20180520","volume":"215","author":"IJ Marie","year":"2018","unstructured":"Marie IJ, Chang HM, Levy DE. HDAC stimulates gene expression through BRD4 availability in response to IFN and in interferonopathies. J Exp Med. 2018;215(12):3194\u2013212.","journal-title":"J Exp Med"},{"issue":"7","key":"1448_CR21","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/nrc1910","volume":"6","author":"D Fukumura","year":"2006","unstructured":"Fukumura D, Kashiwagi S, Jain RK. The role of nitric oxide in tumour progression. Nat Rev Cancer. 2006;6(7):521\u201334.","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"1448_CR22","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.bbcan.2017.09.005","volume":"1868","author":"K Yarlagadda","year":"2017","unstructured":"Yarlagadda K, Hassani J, Foote IP, Markowitz J. The role of nitric oxide in melanoma. Biochim Biophys Acta Rev Cancer. 2017;1868(2):500\u20139.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"6","key":"1448_CR23","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/S0092-8674(01)00495-0","volume":"106","author":"JS Stamler","year":"2001","unstructured":"Stamler JS, Lamas S, ., Fang FC. Nitrosylation. The prototypic redox-based signaling mechanism. Cell. 2001;106(6):675\u2013683.","journal-title":"Cell."},{"issue":"1","key":"1448_CR24","doi-asserted-by":"publisher","first-page":"50","DOI":"10.2174\/156652412798376099","volume":"12","author":"E Aranda","year":"2012","unstructured":"Aranda E, Lopez-Pedrera C, De La Haba-Rodriguez JR, Rodriguez-Ariza A. Nitric oxide and cancer: the emerging role of S-nitrosylation. Curr Mol Med. 2012;12(1):50\u201367.","journal-title":"Curr Mol Med"},{"issue":"5","key":"1448_CR25","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1172\/JCI69611","volume":"124","author":"Q Liu","year":"2014","unstructured":"Liu Q, Tomei S, Ascierto ML, De Giorgi V, Bedognetti D, Dai C, et al. Melanoma NOS1 expression promotes dysfunctional IFN signaling. J Clin Invest. 2014;124(5):2147\u201359.","journal-title":"J Clin Invest"},{"issue":"7211","key":"1448_CR26","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/nature07238","volume":"455","author":"A Nott","year":"2008","unstructured":"Nott A, Watson PM, Robinson JD, Crepaldi L, Riccio A. S-nitrosylation of histone deacetylase 2 induces chromatin remodelling in neurons. Nature. 2008;455(7211):411\u20135.","journal-title":"Nature."},{"key":"1448_CR27","doi-asserted-by":"publisher","first-page":"17011","DOI":"10.1038\/cddiscovery.2017.11","volume":"3","author":"L Zhu","year":"2017","unstructured":"Zhu L, Li L, Zhang Q, Yang X, Zou Z, Hao B, et al. NOS1 S-nitrosylates PTEN and inhibits autophagy in nasopharyngeal carcinoma cells. Cell Death Dis. 2017;3:17011.","journal-title":"Cell Death Dis"},{"issue":"4","key":"1448_CR28","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(\u2212Delta Delta C(T)) Method. Methods (San Diego, Calif). 2001;25(4):402\u20138.","journal-title":"Methods (San Diego, Calif)"},{"issue":"20","key":"1448_CR29","doi-asserted-by":"crossref","first-page":"33047","DOI":"10.18632\/oncotarget.16523","volume":"8","author":"L Li","year":"2017","unstructured":"Li L, Zhu L, Hao B, Gao W, Wang Q, Li K, et al. iNOS-derived nitric oxide promotes glycolysis by inducing pyruvate kinase M2 nuclear translocation in ovarian cancer. Oncotarget. 2017;8(20):33047\u201363.","journal-title":"Oncotarget."},{"key":"1448_CR30","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1038\/nprot.2013.143","volume":"8","author":"FA Ran","year":"2013","unstructured":"Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F. Genome engineering using the CRISPR-Cas9 system. Nat Protoc. 2013;8:2281.","journal-title":"Nat Protoc"},{"issue":"1","key":"1448_CR31","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/nprot.2006.37","volume":"1","author":"T Gustavo","year":"2006","unstructured":"Gustavo T, Oded S, Verma IM. Production and purification of lentiviral vectors. Nat Protoc. 2006;1(1):241\u20135.","journal-title":"Nat Protoc"},{"key":"1448_CR32","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1101\/sqb.2004.69.193","volume":"69","author":"CB Millar","year":"2004","unstructured":"Millar CB, Kurdistani SK, Grunstein M. Acetylation of yeast histone H4 lysine 16: a switch for protein interactions in heterochromatin and euchromatin. Cold Spring Harb Symp Quant Biol. 2004;69:193\u2013200.","journal-title":"Cold Spring Harb Symp Quant Biol"},{"issue":"13","key":"1448_CR33","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1038\/emboj.2011.170","volume":"30","author":"M Oppikofer","year":"2011","unstructured":"Oppikofer M, Kueng S, Martino F, Soeroes S, Hancock SM, Chin JW, et al. A dual role of H4K16 acetylation in the establishment of yeast silent chromatin. EMBO J. 2011;30(13):2610\u201321.","journal-title":"EMBO J"},{"key":"1448_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaut.2017.03.008","volume":"83","author":"K Chen","year":"2017","unstructured":"Chen K, Liu J, Cao X. Regulation of type I interferon signaling in immunity and inflammation: a comprehensive review. J Autoimmun. 2017;83:1\u201311.","journal-title":"J Autoimmun"},{"issue":"2","key":"1448_CR35","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1038\/ncb747","volume":"4","author":"M Paulson","year":"2002","unstructured":"Paulson M, Press C, Smith E, Tanese N, Levy DE. IFN-stimulated transcription through a TBP-free acetyltransferase complex escapes viral shutoff. Nat Cell Biol. 2002;4(2):140\u20137.","journal-title":"Nat Cell Biol"},{"issue":"12","key":"1448_CR36","doi-asserted-by":"publisher","first-page":"6693","DOI":"10.1073\/pnas.95.12.6693","volume":"95","author":"XJ Ma","year":"1998","unstructured":"Ma XJ, Wu J, Altheim BA, Schultz MC, Grunstein M. Deposition-related sites K5\/K12 in histone H4 are not required for nucleosome deposition in yeast. Proc Natl Acad Sci U S A. 1998;95(12):6693\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"1448_CR37","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.bpj.2016.11.015","volume":"112","author":"R Zhang","year":"2017","unstructured":"Zhang R, Erler J, Langowski J. Histone acetylation regulates chromatin accessibility: role of H4K16 in inter-nucleosome interaction. Biophys J. 2017;112(3):450\u20139.","journal-title":"Biophys J"},{"issue":"10","key":"1448_CR38","doi-asserted-by":"publisher","first-page":"5016","DOI":"10.1093\/nar\/gkz195","volume":"47","author":"RG Urdinguio","year":"2019","unstructured":"Urdinguio RG, Lopez V, Bayon GF. Diaz de la Guardia R, sierra MI, Garcia-Torano E, et al. chromatin regulation by histone H4 acetylation at lysine 16 during cell death and differentiation in the myeloid compartment. Nucleic Acids Res. 2019;47(10):5016\u201337.","journal-title":"Nucleic Acids Res"},{"issue":"52","key":"1448_CR39","doi-asserted-by":"publisher","first-page":"13336","DOI":"10.1073\/pnas.1817274115","volume":"115","author":"O Copur","year":"2018","unstructured":"Copur O, Gorchakov A, Finkl K, Kuroda MI, Muller J. Sex-specific phenotypes of histone H4 point mutants establish dosage compensation as the critical function of H4K16 acetylation in drosophila. Proc Natl Acad Sci U S A. 2018;115(52):13336\u201341.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"1448_CR40","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/S0092-8674(02)01077-2","volume":"111","author":"T Agalioti","year":"2002","unstructured":"Agalioti T, Chen G, Thanos D. Deciphering the transcriptional histone acetylation code for a human gene. Cell. 2002;111(3):381\u201392.","journal-title":"Cell."},{"key":"1448_CR41","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.redox.2015.08.009","volume":"6","author":"F Vannini","year":"2015","unstructured":"Vannini F, Kashfi K, Nath N. The dual role of iNOS in cancer. Redox Biol. 2015;6:334\u201343.","journal-title":"Redox Biol"},{"issue":"3","key":"1448_CR42","first-page":"317","volume":"27","author":"M Simone","year":"2010","unstructured":"Simone M, Vincenzo B, Donato N. Nitric oxide, a double edged sword in cancer biology: searching for therapeutic opportunities. Med Res Rev. 2010;27(3):317\u201352.","journal-title":"Med Res Rev"},{"issue":"1","key":"1448_CR43","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1046\/j.1365-2133.1999.02915.x","volume":"141","author":"B Ahmed","year":"1999","unstructured":"Ahmed B, Van Den Oord JJ. Expression of the neuronal isoform of nitric oxide synthase (nNOS) and its inhibitor, protein inhibitor of nNOS, in pigment cell lesions of the skin. Br J Dermatol. 1999;141(1):12\u20139.","journal-title":"Br J Dermatol"},{"issue":"5","key":"1448_CR44","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1089\/ars.2012.4563","volume":"19","author":"Z Yang","year":"2013","unstructured":"Yang Z, Misner B, Ji H, Poulos TL, Silverman RB, Meyskens FL, et al. Targeting nitric oxide signaling with nNOS inhibitors as a novel strategy for the therapy and prevention of human melanoma. Antioxid Redox Signal. 2013;19(5):433\u201347.","journal-title":"Antioxid Redox Signal"},{"issue":"8","key":"1448_CR45","doi-asserted-by":"publisher","first-page":"3113","DOI":"10.1073\/pnas.1218126110","volume":"110","author":"A Nott","year":"2013","unstructured":"Nott A, Nitarska J, Veenvliet JV, Schacke S, Derijck AAHA, Sirko P, et al. S-nitrosylation of HDAC2 regulates the expression of the chromatin-remodeling factor Brm during radial neuron migration. Proc Natl Acad Sci U S A. 2013;110(8):3113\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1448_CR46","doi-asserted-by":"publisher","DOI":"10.1385\/1-59745-024-3:23","volume-title":"Biochemistry of Multiprotein HDAC Complexes","author":"A Vaquero","year":"2006","unstructured":"Vaquero A, Scher M, Reinberg D. Biochemistry of Multiprotein HDAC Complexes; 2006."},{"issue":"1","key":"1448_CR47","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.molonc.2007.01.001","volume":"1","author":"S Ropero","year":"2007","unstructured":"Ropero S, Esteller M. The role of histone deacetylases (HDACs) in human cancer. Mol Oncol. 2007;1(1):19\u201325.","journal-title":"Mol Oncol"},{"issue":"11","key":"1448_CR48","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1158\/2326-6066.CIR-15-0065","volume":"3","author":"J Rautela","year":"2015","unstructured":"Rautela J, Baschuk N, Slaney CY, Jayatilleke KM, Xiao K, Bidwell BN, et al. Loss of host type-I IFN signaling accelerates metastasis and impairs NK-cell antitumor function in multiple models of breast Cancer. Cancer Immunol Res. 2015;3(11):1207\u201317.","journal-title":"Cancer Immunol Res"},{"issue":"2","key":"1448_CR49","doi-asserted-by":"publisher","first-page":"454","DOI":"10.3390\/ijms20020454","volume":"20","author":"Ching-Ling Lin","year":"2019","unstructured":"Lin CL, Tsai ML, Lin CY, Hsu KW, Hsieh WS, Chi WM, et al. HDAC1 and HDAC2 Double Knockout Triggers Cell Apoptosis in Advanced Thyroid Cancer. Int J Mol Sci. 2019;20(2):454.","journal-title":"International Journal of Molecular Sciences"},{"issue":"13","key":"1448_CR50","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1038\/onc.2016.344","volume":"36","author":"N Stojanovic","year":"2017","unstructured":"Stojanovic N, Hassan Z, Wirth M, Wenzel P, Beyer M, Schafer C, et al. HDAC1 and HDAC2 integrate the expression of p53 mutants in pancreatic cancer. Oncogene. 2017;36(13):1804\u201315.","journal-title":"Oncogene."},{"key":"1448_CR51","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.biopha.2016.09.030","volume":"84","author":"L Li","year":"2016","unstructured":"Li L, Mei DT, Zeng Y. HDAC2 promotes the migration and invasion of non-small cell lung cancer cells via upregulation of fibronectin. Biomed Pharmacother. 2016;84:284\u201390.","journal-title":"Biomed Pharmacother"},{"issue":"2","key":"1448_CR52","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.canlet.2008.10.047","volume":"280","author":"W Weichert","year":"2009","unstructured":"Weichert W. HDAC expression and clinical prognosis in human malignancies. Cancer Lett. 2009;280(2):168\u201376.","journal-title":"Cancer Lett"},{"issue":"4","key":"1448_CR53","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/sj.cdd.4401567","volume":"12","author":"BH Huang","year":"2005","unstructured":"Huang BH, Laban M, Leung CH, Lee L, Lee CK, Salto-Tellez M, et al. Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1\/WAF1 expression, independent of histone deacetylase 1. Cell Death Differ. 2005;12(4):395\u2013404.","journal-title":"Cell Death Differ"},{"issue":"2","key":"1448_CR54","first-page":"524","volume":"1846","author":"T Wagner","year":"2014","unstructured":"Wagner T, Brand P, Heinzel T, Kramer OH. Histone deacetylase 2 controls p53 and is a critical factor in tumorigenesis. Biochim Biophys Acta. 2014;1846(2):524\u201338.","journal-title":"Biochim Biophys Acta"},{"issue":"7","key":"1448_CR55","doi-asserted-by":"publisher","first-page":"3145","DOI":"10.1158\/0008-5472.CAN-06-4397","volume":"67","author":"KL Harms","year":"2007","unstructured":"Harms KL, Chen X. Histone deacetylase 2 modulates p53 transcriptional activities through regulation of p53-DNA binding activity. Cancer Res. 2007;67(7):3145\u201352.","journal-title":"Cancer Res"},{"issue":"3","key":"1448_CR56","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/nrc.2016.14","volume":"16","author":"BS Parker","year":"2016","unstructured":"Parker BS, Rautela J, Hertzog PJ. Antitumour actions of interferons: implications for cancer therapy. Nat Rev Cancer. 2016;16(3):131\u201344.","journal-title":"Nat Rev Cancer"},{"key":"1448_CR57","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.cyto.2018.04.006","volume":"118","author":"NK Brockwell","year":"2019","unstructured":"Brockwell NK, Parker BS. Tumor inherent interferons: impact on immune reactivity and immunotherapy. Cytokine. 2019;118:42\u20137.","journal-title":"Cytokine."},{"issue":"15","key":"1448_CR58","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1200\/JCO.2010.30.5037","volume":"29","author":"SM Mahmoud","year":"2011","unstructured":"Mahmoud SM, Paish EC, Powe DG, Macmillan RD, Grainge MJ, Lee AH, et al. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol. 2011;29(15):1949\u201355.","journal-title":"J Clin Oncol"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-019-1448-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13046-019-1448-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-019-1448-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T20:22:32Z","timestamp":1665174152000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-019-1448-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1448"],"URL":"https:\/\/doi.org\/10.1186\/s13046-019-1448-9","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"19 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All animal experiments in this study were approved by the Medical Ethics Committee of Southern Medical University and conducted in strict accordance with the guidelines from the Ministry of Science and Technology of China.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not application.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"483"}}